MapLight Therapeutics, Inc. (MPLT) AI Stock Analysis

• Market Cap: $783.59M
• Dividend Yield: N/A
• Average Volume (3M): 401.63K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.40
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 109
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 45,373,030
• 10 Day Avg. Volume: 205,334
• 30 Day Avg. Volume: 401,626
• PEG Ratio: -0.25
• Price to Book (P/B): 6.60
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.55
• Enterprise Value/Market Cap: -0.06
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 101.02
• Enterprise Value/Ebitda: 0.42
• 1Y Price Target: $31.00
• Price Target Upside: 79.71% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -3.69
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $17.50 ▲(1.45% Upside)
• Action: Reiterated Date: 01/09/26
• Date: Action: Reiterated 01/09/26

The score is held back primarily by pre-revenue financials with widening losses and increasing cash burn, partially offset by a comparatively strong, low-leverage balance sheet. Recent corporate events (large IPO/private placement and stated runway through 2027) improve near-term funding visibility, while technical indicators are mixed/neutral and valuation cannot be assessed from the provided data.

Positive Factors

Low leverage / strong balance sheet

Very low debt relative to equity gives durable financial flexibility for a clinical-stage biotech. It supports continued R&D investment, reduces short-term solvency risk, and allows the company to fund operations or opportunistic partnerships without being forced into distressed financing.

Material capital raise and runway

A sizable raise materially extends operational runway through stated 2027 timeframe. This reduces immediate dilution pressure, funds multiple Phase 2 programs, and increases the probability management can reach key clinical readouts before needing additional financing, a durable support for execution.

Regulatory progress: Fast Track designation

Fast Track status signals regulatory recognition of unmet need and enables more frequent FDA interactions and potential accelerated review. Structurally this can shorten development timelines and improve program de-risking if clinical data are positive, strengthening long-term program value.

Negative Factors

Pre-revenue with widening net losses

Sustained, expanding losses are a structural risk for a clinical-stage company: absent commercial revenue the business is reliant on financing markets and milestone success. Persistent widening losses increase the likelihood of future dilutive financings and place a premium on achieving clinical proof points.

Accelerating cash burn and negative free cash flow

Operating losses are translating directly into large negative cash flows, increasing near-term financing needs. While predictable for a developer, the scale of burn reduces optionality, heightens dilution risk if trials slip, and limits ability to invest beyond core programs without new capital.

Deeply negative returns and binary program risk

Deep negative ROE shows capital deployed is not generating shareholder returns, typical for pre-commercial biotechs. Long-term value creation depends on binary clinical/regulatory outcomes; failure or delays can crystallize dilution and impair returns for existing investors over the medium term.

MapLight Therapeutics, Inc. Business Overview & Revenue Model

Company Description

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. MapLight Therapeutics, Inc. was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California. MapLight Therapeutics, Inc operates as a subsidiary of Catalyst4, Inc.

How the Company Makes Money

MapLight Therapeutics, Inc. Financial Statement Overview

Summary

Income statement and cash flow are weak: the company is pre-revenue with widening losses and accelerating operating/free cash outflows. The balance sheet is a relative strength with low leverage versus equity, but deeply negative returns and rising burn create ongoing financing/dilution risk.

Income Statement

The company is pre-revenue (revenue is 0 across 2022–2024), and losses are widening: net loss increased from about $30.0M (2022) to $55.7M (2023) to $77.6M (2024). Operating performance is consistently negative, with EBIT declining from roughly -$31.2M (2022) to -$82.9M (2024). A key strength is that there’s no evidence of revenue volatility risk yet because there is no commercial revenue base, but the main weakness is the accelerating cash burn and expanding losses typical of a development-stage biotech.

Balance Sheet

Leverage looks manageable: total debt is ~$6.6M against stockholders’ equity of ~$115.2M in 2024, and the debt-to-equity ratio improved to ~0.06 (from ~0.30 in 2022). The balance sheet has also scaled up (assets rose from ~$39.4M in 2022 to ~$136.9M in 2024), supporting ongoing R&D investment. The major weakness is profitability/return profile—return on equity remains deeply negative (around -0.67 in 2024), indicating continued value dilution risk unless funding translates into future revenue.

Cash Flow

Cash generation is weak and deteriorating: operating cash flow fell from about -$26.6M (2022) to -$52.0M (2023) to -$78.8M (2024), and free cash flow was similarly negative (-$79.6M in 2024). Free cash flow broadly tracks net loss (free cash flow to net income is ~1.0 each year), suggesting losses are translating directly into cash burn rather than being cushioned by non-cash items. A positive is that the cash flow profile appears consistent/predictable for a pre-revenue biotech, but the scale of the burn is increasing and will likely require ongoing financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	0.00	0.00	0.00	0.00
Gross Profit	-438.00K	-701.00K	-556.00K	-574.00K
EBITDA	-105.83M	-76.88M	-55.15M	-29.44M
Net Income	-102.83M	-77.58M	-55.71M	-30.02M
Balance Sheet
Total Assets	257.22M	136.92M	91.41M	39.39M
Cash, Cash Equivalents and Short-Term Investments	227.17M	108.80M	79.77M	27.66M
Total Debt	6.01M	6.58M	5.92M	6.27M
Total Liabilities	23.70M	21.72M	20.13M	18.52M
Stockholders Equity	233.52M	115.19M	71.28M	20.87M
Cash Flow
Free Cash Flow	-113.00M	-79.58M	-52.47M	-27.32M
Operating Cash Flow	-112.80M	-78.81M	-52.01M	-26.58M
Investing Cash Flow	-48.26M	-80.79M	-462.00K	-746.00K
Financing Cash Flow	197.86M	118.06M	104.57M	33.17M

MapLight Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MPLT	52 Neutral	$783.59M	―	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SNSE	51 Neutral	$38.47M	-1.43	-67.47%	―	―	9.63%
SCNI	49 Neutral	$757.97K	-0.07	―	―	178.82%	-4121.10%
DRMA	47 Neutral	$3.40M	-0.06	-203.36%	―	―	90.53%
GRI	43 Neutral	$3.68M	-0.01	-238.17%	―	―	98.22%
AZTR	41 Neutral	$1.88M	-0.05	-215.04%	―	-100.00%	93.82%

MapLight Therapeutics, Inc. Corporate Events

MapLight updates trial timelines and highlights CNS pipeline

On January 9, 2026, MapLight Therapeutics announced it now expects topline Phase 2 results for its ZEPHYR and IRIS clinical trials—evaluating ML-007C-MA in schizophrenia and ML-004 in autism spectrum disorder—to be disclosed in the third quarter of 2026, a timing update that investors will monitor closely given the programs’ potential to address significant unmet needs in CNS disorders. The company also updated its corporate presentation for investor and analyst meetings, underscoring a broad CNS pipeline, projected milestones across schizophrenia, Alzheimer’s disease psychosis, autism spectrum disorder, Parkinson’s disease and other indications, and a strong capital position that may support continued clinical execution and reinforce its competitive positioning in the emerging muscarinic and circuit-targeted therapeutics space.

The most recent analyst rating on (MPLT) stock is a Hold with a $16.50 price target. To see the full list of analyst forecasts on MapLight Therapeutics, Inc. stock, see the MPLT Stock Forecast page.

MapLight Therapeutics Completes IPO and Raises $296.5M

MapLight Therapeutics reported its third-quarter 2025 financial results, highlighting significant progress in its clinical trials and financial stability. The company completed an initial public offering and private placement in October 2025, raising $296.5 million, which will fund operations through 2027. Key developments include the initiation of Phase 2 trials for ML-007C-MA for schizophrenia and Alzheimer’s disease psychosis, with results expected in 2026 and 2027 respectively, and the completion of enrollment in the IRIS Phase 2 study for autism spectrum disorder. The company ended the quarter with $227.2 million in cash, cash equivalents, and short-term investments, despite a net loss of $29.4 million.

The most recent analyst rating on (MPLT) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on MapLight Therapeutics, Inc. stock, see the MPLT Stock Forecast page.

MapLight Therapeutics Closes Successful IPO and Private Placement

MapLight Therapeutics, Inc. successfully closed its initial public offering (IPO) on October 28, 2025, issuing 14,750,000 shares of common stock at $17.00 per share, with underwriters exercising an option to purchase an additional 2,212,500 shares. Concurrently, the company completed a private placement with Goldman Sachs affiliates, raising gross proceeds of $296.3 million from both the IPO and private placement, which will enhance its financial position and market presence.